Profil bibliographique

Daniel P. Petrylak

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
1Citations signalées
1Affiliations récentes

Les institutions déclarées

Yale University

Les domaines associés

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchLung Cancer Treatments and MutationsBladder and Urothelial Cancer TreatmentsWnt/β-catenin signaling in development and cancer

Les publications récentes

2026 conference-abstract OpenAlex

Efficacy and safety of enzalutamide (ENZA) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities (CMDs) and/or related concomitant medications (meds): ARCHES post hoc.

A Stenzl, Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore et autres

5092 Background: In ARCHES, ENZA improved radiographic progression-free survival (rPFS; primary: data cutoff, Oct 14, 2018) and overall survival (OS; prespecified secondary: data cutoff, May 28, 2021; 5-yr follow-up; data cutoff: Jul 31, 2024) vs placebo (PBO) in mHSPC. Our objective was …

de, gb, us, fr, es, ru, jp, cn, au (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Accès ouvert 2026 conference-abstract OpenAlex

Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) in patients (pts) with previously treated locally advanced/metastatic urothelial carcinoma (la/mUC).

Daniel P. Petrylak, Mauricio Burotto, Felipe Reyes-Cosmelli, Hernan Javier Cutuli et autres

4566 Background: Zele is a highly selective Bicycle Drug Conjugate (BDC) targeting Nectin-4, a protein overexpressed in la/mUC. There remains an unmet need in la/mUC for safer and more tolerable treatments. Here, we report an interim analysis (IA) for zele monotherapy dosage …

us, cl, gb, es, kr, fr (code pays fourni par la source)

1 citation Journal of Clinical Oncology
2026 conference-abstract OpenAlex

Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.

Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore, Russell Z. Szmulewitz et autres

5093 Background: In ARCHES (NCT02677896), ENZA + androgen-deprivation therapy (ADT) significantly improved radiographic progression-free survival (primary: data cutoff, Oct 14, 2018) and overall survival (prespecified secondary: data cutoff, May 28, 2021; 5-year follow-up: data cutoff, Jul 31, 2024) vs placebo + ADT …

gb, us, fr, es, ru, jp, de, au (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.